BRPI0520433A2 - sais farmaceuticamente aceitáveis de 2,4,6-trimetil-3-hidroxipiridina, com ácidos dicarboxìlicos inferiores e método para preparação dos mesmos - Google Patents

sais farmaceuticamente aceitáveis de 2,4,6-trimetil-3-hidroxipiridina, com ácidos dicarboxìlicos inferiores e método para preparação dos mesmos

Info

Publication number
BRPI0520433A2
BRPI0520433A2 BRPI0520433-0A BRPI0520433A BRPI0520433A2 BR PI0520433 A2 BRPI0520433 A2 BR PI0520433A2 BR PI0520433 A BRPI0520433 A BR PI0520433A BR PI0520433 A2 BRPI0520433 A2 BR PI0520433A2
Authority
BR
Brazil
Prior art keywords
trimethyl
hydroxypyridine
pharmaceutically acceptable
acceptable salts
dicarboxylic acids
Prior art date
Application number
BRPI0520433-0A
Other languages
English (en)
Inventor
Leonid Dmitrievich Smipnov
Michail Arkadievich Ostrovsky
Aleksey Michailovich Sipyagin
Aleksandr Evgenievich Doncov
Original Assignee
Marvel Lifesciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marvel Lifesciences Ltd filed Critical Marvel Lifesciences Ltd
Publication of BRPI0520433A2 publication Critical patent/BRPI0520433A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SAIS FARMACEUTICAMENTE ACEITáVEIS DE 2,4,6-TRIMETIL-3-HIDROXIPIRIDINA, COM áCIDOS DICARBOXìLICOS INFERIORES E MéTODO PARA PREPARAçãO DOS MESMOS. A presente invenção refere-se ao campo de medicamentos, notadamente, a novos compostos biologicamente ativos, especificamente, a derivados de 2,4,6-trimetil-3-hidroxipiridina e sais dos mesmos (composto 1), apresentando atividade antioxidante, geroprotetora e antiisquêmica. Os sais do composto (1) são preparados mediante reação de quantidades eqúimolares de 2,4,6-trimetil-3-hidroxipiridina e ácido dicarboxílico, em uma solução de um álcool inferior a uma temperatura de 6O-100°C, seguido de tratamento da massa reacional com um solvente orgânico por 2-5 horas, a uma temperaturade 1O-15°C.
BRPI0520433-0A 2004-05-12 2005-07-11 sais farmaceuticamente aceitáveis de 2,4,6-trimetil-3-hidroxipiridina, com ácidos dicarboxìlicos inferiores e método para preparação dos mesmos BRPI0520433A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2004114314/04A RU2276138C2 (ru) 2004-05-12 2004-05-12 Вещество, обладающее антиоксидантной, геропротекторной и противоишемической активностью, и способ его получения
PCT/IB2005/003636 WO2007017713A1 (fr) 2004-05-12 2005-07-11 Substance possedant un effet antioxydant, geroprotecteur et anti-ischemique et procede de fabrication correspondant

Publications (1)

Publication Number Publication Date
BRPI0520433A2 true BRPI0520433A2 (pt) 2009-05-12

Family

ID=36021747

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520433-0A BRPI0520433A2 (pt) 2004-05-12 2005-07-11 sais farmaceuticamente aceitáveis de 2,4,6-trimetil-3-hidroxipiridina, com ácidos dicarboxìlicos inferiores e método para preparação dos mesmos

Country Status (11)

Country Link
US (1) US8044210B2 (pt)
EP (1) EP1911746B1 (pt)
JP (1) JP2009501712A (pt)
CN (1) CN101233110B (pt)
AT (1) ATE440819T1 (pt)
BR (1) BRPI0520433A2 (pt)
CA (1) CA2614857A1 (pt)
DE (1) DE602005016317D1 (pt)
PL (1) PL1911746T3 (pt)
RU (1) RU2276138C2 (pt)
WO (1) WO2007017713A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2276138C2 (ru) 2004-05-12 2006-05-10 Марвел Лайф Сайнсез Лтд. Вещество, обладающее антиоксидантной, геропротекторной и противоишемической активностью, и способ его получения
RU2326665C1 (ru) * 2007-04-03 2008-06-20 Марвел ЛайфСайнсез Лимитед, Великобритания Средство, обладающее противогипоксическим, противоинсультным, улучшающим память действием
EA011238B1 (ru) * 2007-04-03 2009-02-27 Марвел Лайфсайнсез Лтд. Средство, обладающее противогипоксическим, противоинсультным, улучшающим память действием
CN101903352B (zh) * 2007-12-18 2013-07-10 德米特里·瓦莱利维奇·比留科夫 取代的3-羟基吡啶系化合物及其药物组合物
EP2265252A2 (en) * 2008-02-19 2010-12-29 Marvel Lifesciences Limited Ophthalmic preparation containing a pyridinol derivate
WO2009116078A2 (en) * 2008-02-19 2009-09-24 M. J. Biopharm Pvt. Ltd. Oral dosage formulations and process of preparation thereof
EP2252265A4 (en) * 2008-02-19 2011-04-20 Marvel Lifesciences Ltd INJECTABLE PREPARATIONS AND MANUFACTURING METHOD THEREFOR
EA020371B1 (ru) 2012-07-19 2014-10-30 Хэндельсорт Аг Алкилзамещенные 3-гидроксипиридины для лечения депрессии
RU2671200C2 (ru) * 2015-12-07 2018-10-30 Закрытое Акционерное Общество "Фармфирма "Сотекс" Способ получения 6-метил-2-этилпиридин-3-ол соли (2S)-2-ацетаминопентандиовой кислоты

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2847926B2 (ja) * 1990-08-01 1999-01-20 トヨタ自動車株式会社 自動変速機の変速制御装置
JPH0496277A (ja) * 1990-08-06 1992-03-27 Fujitsu Ltd 不揮発性半導体記憶装置
IT1247528B (it) * 1991-04-24 1994-12-17 Medea Res Srl Composto ad attivita' terapeutica,sua preparazione e composizioni farmaceutiche che lo contengono
RU2070010C1 (ru) * 1993-08-31 1996-12-10 Эдуард Сергеевич Аветисов Средство антиоксидантной защиты сред и тканей глаза
RU2112512C1 (ru) 1995-09-22 1998-06-10 Иванов Евгений Васильевич Биологичеcки активная пищевая добавка "глутапирон", обладающая антиканцерогенным и геропротекторным действием
RU2153872C2 (ru) * 1997-10-15 2000-08-10 Амбалов Юрий Михайлович Способ лечения дифтерии
RU2197199C2 (ru) * 2000-05-12 2003-01-27 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ лечения амблиопии
JP2002017295A (ja) * 2000-07-05 2002-01-22 Yamagami Suehito 眼疾患改善作用及び眼の機能維持作用を有する健康補助食品
RU2210568C1 (ru) * 2001-12-14 2003-08-20 Промоненков Виктор Кириллович Способ получения производных 2-этил-6-метил-3-гидроксипиридина
RU2250210C1 (ru) * 2003-07-25 2005-04-20 Институт Проблем Химической Физики Российской Академии Наук (Ипхф Ран) Нитроксисукцинат 2,4,6-триметил-3-оксипиридина и способ его получения
RU2276138C2 (ru) 2004-05-12 2006-05-10 Марвел Лайф Сайнсез Лтд. Вещество, обладающее антиоксидантной, геропротекторной и противоишемической активностью, и способ его получения

Also Published As

Publication number Publication date
RU2276138C2 (ru) 2006-05-10
PL1911746T3 (pl) 2010-07-30
EP1911746B1 (en) 2009-08-26
US20090198068A1 (en) 2009-08-06
WO2007017713A1 (fr) 2007-02-15
CN101233110A (zh) 2008-07-30
DE602005016317D1 (de) 2009-10-08
CN101233110B (zh) 2011-09-14
ATE440819T1 (de) 2009-09-15
JP2009501712A (ja) 2009-01-22
US8044210B2 (en) 2011-10-25
CA2614857A1 (en) 2007-02-15
EP1911746A1 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
EP1698624A4 (en) phenylpropanoic acid derivatives
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
BR0315047A (pt) Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
ATE358484T1 (de) Antidiabetische medikamente
BRPI0520433A2 (pt) sais farmaceuticamente aceitáveis de 2,4,6-trimetil-3-hidroxipiridina, com ácidos dicarboxìlicos inferiores e método para preparação dos mesmos
NO20044449L (no) Salter av tolterodin
DK1018511T3 (da) Isochromanforbindelser og fremgangsmåde til deres fremstilling
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
WO2007105021A3 (en) Duloxetine salts
CA1331419C (en) Peptides with pharmaceutical activity
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
EE200200599A (et) Tsüklipostiiniühend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,ühendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
NO20054418L (no) Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse
EP1589023A4 (en) oligosaccharide
BRPI0404006A (pt) Compostos de benzoindolina, processo para sua preparação e composições farmacêuticas contendo os mesmos
ATE493988T1 (de) Pyrimidinderivate enthaltendes medikament
PT916656E (pt) Metodo para producao de derivados de pirrolidinona
TH84551A (th) อนุพันธ์ n-(เฮเทอโรแอริล)-1h-อินโดล-2-คาร์บอกซาไมด์, การเตรียมสารดังกล่าว และการใช้สารดังกล่าวทางการบำบัด
TH76305A (th) อนุพันธ์ไซคลิกยูเรียถูกแทนที่
EP1170287A4 (en) METHOD FOR PRODUCING OPTICALLY ACTIVE, N-SUBSTITUTED AZETIDINE-2-CARBONIC ACIDS
TH79586A (th) สารประกอบอินทรีย์

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2203 DE 26/03/2013.